Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC).
Year: 2015
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Naiyer A. Rizvi, Julie R. Brahmer, Sai-Hong Ignatius Ou, Neil Howard Segal, Samir Khleif, Wen-Jen Hwu, Martin Gutierrez, Patrick Schoffski, Omid Hamid, Jared Weiss, Jose Lutzky, Michele Maio, John J. Nemunaitis, Dirk Jaeger, Ani Sarkis Balmanoukian, Marlon Rebelatto, Keith Steele, Xia Li, John A. Blake-Haskins, Scott Joseph Antonia
Institutions: Columbia University Irving Medical Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, University of California, Irvine, UC Irvine Health, Memorial Sloan Kettering Cancer Center, Augusta University, The University of Texas MD Anderson Cancer Center, Hackensack University Medical Center, Universitair Ziekenhuis Leuven, Angeles Clinic and Research Institute, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, University of Siena, Mary Crowley Cancer Research Center, University Hospital Heidelberg, National Center for Tumor Diseases, Moffitt Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2230051264